Skip to main content
SpringerLink
Log in

Eczematous eruption in patients with psoriasis during risankizumab treatment

  • Correspondence
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nast A, Amelunxen L, Augustin M, et al. S3 Guideline for the treatment of psoriasis vulgaris, update — Short version part 1 — Systemic treatment. J Dtsch Dermatol Ges 2018; 16: 645–69.

    PubMed  Google Scholar 

  2. Sondermann W, Herz S, Sody E, Korber A. Dermatological complications of therapy with biologics in inflammatory autoimmune diseases. J Dtsch Dermatol Ges 2019; 17: 1029–37.

    PubMed  Google Scholar 

  3. Nakamura M, Lee K, Singh R, et al. Eczema as an adverse effect of anti-TNFalpha therapy in psoriasis and other Th1-mediated diseases: a review. J Dermatolog Treat 2017; 28: 237–41.

    Article  CAS  Google Scholar 

  4. Esmailzadeh A, Yousefi P, Farhi D, et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology 2009; 219: 263–7.

    Article  Google Scholar 

  5. Napolitano M, Megna M, Fabbrocini G, et al. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol 2019; 181: 604–6.

    Article  CAS  Google Scholar 

  6. Ishiuji Y, Umezawa Y, Asahina A, et al. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases. J Dermatol 2018; 45: 732–4.

    Article  CAS  Google Scholar 

  7. Reyn B, Hillary T, Gils A. Eczematous eruption after guselkumab treatment for psoriasis. JAAD Case Rep 2019; 5: 973–5.

    Article  Google Scholar 

  8. Truong A, Le S, Kiuru M, Maverakis E. Nummular dermatitis on guselkumab for palmoplantar psoriasis. Dermatol Ther 2019; 32: e12954.

    Article  Google Scholar 

  9. Eyerich S, Onken AT, Weidinger S, et al. Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med 2011; 365: 231–8.

    Article  CAS  Google Scholar 

  10. Al-Janabi A, Foulkes AC, Mason K, Smith CH, Griffiths C, Warren RB. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2020; 34: 1440–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Venereology, and Allergology, University Medical Center, Göttingen, Germany, Robert Koch Straße 40, D-37075, Göttingen, Germany

    Christian Kromer, Michael P. Schön & Rotraut Mössner

  2. Lower Saxony Institute of Occupational Dermatology, University Medical Center, Göttingen, Germany

    Michael P. Schön

Authors
  1. Christian Kromer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael P. Schön
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rotraut Mössner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rotraut Mössner.

Additional information

Disclosure

Conflicts of interest: C. Kromer has been an advisor and/or received speakers’ honoraria from Janssen-Cilag and Novartis. M.-P. Schön has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials for the following companies: Abbvie, Celgene, Janssen-Cilag, Leo, Lilly, Novartis and UCB. R. Mössner has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials for the following companies: Abbott/Abbvie, Allmirall, Biogen IDEC GmbH, Böhringer-Ingelheim, Celgene, Janssen-Cilag GmbH, Leo Pharma GmbH, Lilly, MSD SHARP & DOHME GmbH, Novartis Pharma GmbH, Pfizer GmbH and UCB. Funding sources: none.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kromer, C., Schön, M.P. & Mössner, R. Eczematous eruption in patients with psoriasis during risankizumab treatment. Eur J Dermatol 30, 599–601 (2020). https://doi.org/10.1684/ejd.2020.3871

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2020.3871

Search

Navigation